Pilot study of recombinant interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus.
Eleven children with bronchiolitis induced by respiratory syncytial virus received 10,000 to 70,000 U of recombinant interferon alpha-2a per kg of body weight per day. None developed signs of toxicity, and all but one developed an antiviral state following treatment. Interferon alpha-2a appears to be safe for infants with bronchiolitis. Its efficacy for the treatment of this condition remains to be determined.
Portnoy
J
J
Section of Allergy/Immunology Diseases, Children's Mercy Hospital, Kansas City, Missouri.
Hicks
R
R
Pacheco
F
F
Olson
L
L
D000906:Antibodies / Q000032:analysis; D001681:Biological Assay; D001990:Bronchiolitis, Viral / Q000382:microbiology / Q000628:therapy*; D006801:Humans; D007223:Infant; D007370:Interferon Type I / Q000032:analysis / Q000276:immunology / Q000627:therapeutic use*; D010865:Pilot Projects; D012136:Respiratory Syncytial Viruses / Q000187:drug effects; D010253:Respirovirus Infections / Q000628:therapy*
D000906:Antibodies; D007370:Interferon Type I